RET and neoplasm: A phase I study of HS-10365 has assessed the safety, tolerability, PK and anti-tumor activity in RET-altered solid tumors [46] (NCT05207787, accessed 3 November 2023), including RET fusion–positive NSCLC and RET-mutated MTC.